SNY
$44.06
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions.
Intraday
Recent News
Top Stock Reports for GE Aerospace, Shell & McKesson
GE Aerospace gains on strong engine demand and defense tailwinds, while Shell and McKesson navigate mixed performance and strategic shifts.
Big drugmakers must face US overcharge claims on medications for low-income patients
By Jonathan Stempel March 17 (Reuters) - A U.S. appeals court on Tuesday revived a whistleblower lawsuit accusing four large drugmakers of defrauding the federal and state governments out of hundreds
Transient but transformative: Sanofi’s mRNA CAR-T enters in vivo race
Sanofi’s agent uses mRNA that produces transient CAR-T cells, allowing repeated dosing.
Is There Now An Opportunity In Sanofi (ENXTPA:SAN) After A 25% Share Price Slide?
Investors may be wondering whether Sanofi’s current share price really reflects its underlying worth, or if the market is mispricing it. The stock most recently closed at €76.39, with returns of 0.8% over 7 days, a 1.6% decline over 30 days, a 7.2% decline year to date, and a 25.8% decline over the last year. These moves may have changed how investors think about both its potential and its risks. Recent coverage has focused less on short-term trading and more on Sanofi’s fundamentals and...
Is Pfizer Inc. (PFE) One of Goldman Sachs Top Healthcare Stocks?
Pfizer Inc. (NYSE:PFE) is one of Goldman Sachs top healthcare stocks. On March 9, analysts at BMO reiterated an Outperform rating on Pfizer Inc. (NYSE:PFE) and a $30 price target. The bullish stance follows positive phase 2 data on the company’s tri-specific antibody tilrekimig. Trial results showed that the once-a-month inhibitor achieved a placebo-adjusted high […]